MARKET

PULM

PULM

Pulmatrix
NASDAQ
1.930
-0.050
-2.53%
Closed 16:00 06/24 EDT
OPEN
1.920
PREV CLOSE
1.980
HIGH
1.970
LOW
1.900
VOLUME
7.71K
TURNOVER
0
52 WEEK HIGH
2.840
52 WEEK LOW
1.550
MARKET CAP
7.05M
P/E (TTM)
-0.7967
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at PULM last week (0617-0621)?
Weekly Report · 22h ago
Weekly Report: what happened at PULM last week (0610-0614)?
Weekly Report · 06/17 09:42
Weekly Report: what happened at PULM last week (0603-0607)?
Weekly Report · 06/10 09:43
Weekly Report: what happened at PULM last week (0527-0531)?
Weekly Report · 06/03 09:44
Pulmatrix Enters Cross License Agreement With MannKind - Quick Facts
NASDAQ · 05/29 13:17
PULMATRIX INC - AS PART OF TRANSACTION, MANNKIND WILL ASSUME LEASE OF BEDFORD, MASS., R&D FACILITY
Reuters · 05/29 12:45
Weekly Report: what happened at PULM last week (0520-0524)?
Weekly Report · 05/27 09:45
Weekly Report: what happened at PULM last week (0513-0517)?
Weekly Report · 05/20 09:43
More
About PULM
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as acute migraine and serious lung diseases, such as chronic obstructive pulmonary disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). The Company’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes. The Company’s therapeutic candidates include PUR3100, PUR1800, and PUR1900. PUR3100 is the iSPERSE formulation of dihydroergotamine (DHE), for the treatment of acute migraine.

Webull offers Pulmatrix Inc stock information, including NASDAQ: PULM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PULM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PULM stock methods without spending real money on the virtual paper trading platform.